The annual public report from the Joint Drug Prevention and Treatment Program’s Independent Program Administrator has been released by Major League Baseball. The stats:
- There were 5,391 total drug tests. 4,022 were urine samples, 1,369 were blood samples;
- There were eight positive tests resulting in discipline. All were for stimulants. Seven of the stimulant tests were for Adderall. One for Methylhexaneamine. I guess that means that there are no more steroids in baseball. Yay!
- There were 13 “non-analytical positives.” That’s baseball code for “Biogenesis dudes.”
- There were 122 therapeutic use exemptions for otherwise banned drugs. 119 of them were for ADD drugs like Adderall. Three were three for hypogonadism. A couple of years ago here was only one for hypogonadism, so that’s on the uptick. On the bright side, two years ago there was a therapeutic use exemption for narcolepsy and now there is none. So the narcoleptic either got better or retired.
The most interesting thing here, to me anyway, continues to be the number of Adderall-users in baseball. It’s estimated that 4.7% of the adult population has ADD. 119 of roughly 1,200 major leaguers on 40-man rosters puts the ADD rate at nearly 10%. Back that number down a little bit for the various guys that shuffle in and out of 400-man rosters and you figure that baseball players have ADD diagnosis at around twice the level of that in the normal population.
Are baseball players more likely to have ADD than the rest of the adult population? Are they just more likely to be diagnosed that way? Or are therapeutic use exemptions for ADD drugs a means of getting something ballplayers have always found beneficial — stimulants — in a legal way?
The Mets are currently enjoying the spoils of the best young rotation in the game, but the big question is whether this is just a brief window or the start of sustained success. Given the huge prices on the free agent market, it’s going to be next to impossible to keep the band together, but at least one member of the rotation is open to sticking around for the long-term.
While there haven’t been any talks yet, All-Star right-hander Jacob deGrom told Kevin Kernan of the New York Post that he could see himself discussing an extension with the Mets.
“I’m a little bit older, so I might be more willing to do something like that,’’ deGrom told The Post at Mets pre-camp. “You just have to look at what is fair so both sides get a decent deal. It’s something I’d have to look into and make sure I agree with it.’’
It makes sense from deGrom’s perspective. He broke into the majors later than most prospects, so he’ll be 28 this June. Depending on whether he qualifies as a Super Two, he’ll be arbitration-eligible for the first time after either 2016 or 2017. Either way, he’s under team control through 2020, which means that he’s currently on track to hit free agency after his age-32 season. The market might not be kind to him even if he manages to stay healthy, so it could behoove him to get as much guaranteed money as possible right now. The Mets could always decide to play things year-to-year, but perhaps deGrom would be willing to settle for a discount in order to get them to buy out a free agent year or two. It’s a really interesting situation to think about, but odds are the two sides will wait on contract talks until he’s arbitration-eligible for the first time.
DeGrom owns a 2.61 ERA in 52 starts over his first two seasons in the majors. Among starters, only Zack Greinke, Jake Arrieta, and Clayton Kershaw have a lower ERA since the start of 2014.
The Royals and third baseman Mike Moustakas have avoided arbitration by agreeing to a two-year, $14.3 million deal, reports Jon Heyman of MLB Network.
The deal, which was initially discussed last month, buys out Moustakas’ final two years of arbitration. Jeffrey Flanagan of MLB.com reports that it’s believed he’ll make $5.6 million in 2016 and $8.7 million in 2017.
The 27-year-old Moustakas posted an underwhelming .668 OPS over his first four seasons in the majors, but he enjoyed a big postseason in 2014 before breaking out last season by batting .284/.348/.470 with 22 home runs and 82 RBI.
ESPN’s Jerry Crasnick reported this morning that free agent reliever Tommy Hunter required core muscle repair surgery earlier this offseason. Coming off a disappointing 2015, it’s understandable why he’s still on the market, but it sounds like he has at least one significant lead.
Marc Topkin of the Tampa Bay Times hears that the Rays are having “advanced talks” with Hunter as they attempt to add an experienced arm to their bullpen. Nothing is considered close and Hunter is also talking to other clubs. Meanwhile, the Rays have been in touch with veteran reliever Ryan Webb while monitoring the trade market.
Hunter posted a 2.88 ERA as a late-inning arm from 2013-2014, but he compiled a mediocre 4.18 ERA over 58 appearances last season between the Orioles and Cubs. On the bright side, his velocity has held steady and his control is still very good. Despite the down year and core muscle surgery, Topkin writes that Hunter may be holding out for a multi-year deal.
Eric O'Flaherty wasn’t the only reclamation project added by the Pirates today, as the club also announced that they have signed left-hander Cory Luebke to a minor league contract with an invitation to spring training.
Luebke once looked like a solid rotation piece for the Padres, but he hasn’t thrown a pitch in the majors since April 27, 2012. He’s undergone a pair of Tommy John surgeries since. Now 30 years old, he logged seven innings in the minors last season before requiring a procedure to remove loose bodies around a nerve in his forearm. The Padres cut ties with him in November after declining a $7.5 million club option for 2016.
It’s hard to count on much from Luebke at this point, but he told Adam Berry of MLB.com that he feels healthy and hopes to compete for a bullpen job in the spring.